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Abstract
Although statins and other pharmacological approaches have improved the management of lipid 
abnormalities, there exists a need for newer treatment modalities especially for the management of 
hypertriglyceridemia. Lipoprotein lipase (LPL), by promoting hydrolytic cleavage of the 
triglyceride core of lipoproteins, is a crucial node in the management of plasma lipid levels. 
Although LPL expression and activity modulation is observed as a pleiotropic action of some the 
commonly used lipid lowering drugs, the deliberate development of drugs targeting LPL has not 
occurred yet. In this review, we present the biology of LPL, highlight the LPL modulation 
property of currently used drugs and review the novel emerging approaches to target LPL.
Introduction
Homeostatic balance of fat absorption, synthesis and breakdown is crucial to the metabolic 
health of humans. The dietary lipids absorbed via the small intestine and the lipids carried in 
the form of lipoproteins generated by the liver are the major contributors to circulatory lipid 
levels and comprise the exogenous and endogenous pathways of lipid transport, respectively. 
The circulatory lipids in exogenous and endogenous lipid transport pathways converge on a 
catabolic enzyme named lipoprotein lipase (LPL). The enzymatic activity of LPL is central 
to the maintenance of plasma lipid levels in check in the face of excessive fat intake or 
dysregulated lipid metabolism in the liver. As such, LPL has slowly but definitively emerged 
as a drug target in dyslipidemia.
Lipases are the orchestrators of fat digestion and absorption, metabolism of lipoproteins and 
mobilization of stored depots of fats to oxidative tissues in conditions of nutrient demand. 
The catalytic reaction that facilitates the role of LPL in these processes is the hydrolytic 
cleavage of the ester bonds of the triacylglycerols (TGs) to form glycerol and free fatty 
acids. This hydrolytic processing of lipids known as lipolysis is carried out in the 
gastrointestinal tract (pancreatic lipase, gastric lipase, among others), intracellularly [adipose 
triglyceride lipase (ATGL), hormone-sensitive lipase, among others], as well as in 
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circulatory blood vessels. In the vasculature, the key lipases are LPL, endothelial lipase (EL) 
and hepatic lipase (HL). These three lipases differ in the relative ratios of their triglyceride 
lipase to phospholipase activity [1]. Although all three enzymes are involved in triglyceride 
metabolism, the current review will focus on LPL as a drug target in metabolic diseases.
LPL: structure, function and regulation
LPL is primarily synthesized in the heart, skeletal muscle and adipose tissue. Other tissues 
with measurable LPL activity include lungs, lactating mammary glands, brain, kidney and 
macrophages. In all tissues, LPL is found lining the capillary endothelial lumen and its main 
function is to hydrolyze the core triglycerides in the triglyceride-rich lipoproteins such as the 
chylomicrons and the very-low-density lipoproteins (VLDLs) yielding glycerol and free 
fatty acids (FFAs) for uptake by tissues. Apart from TG hydrolysis, LPL in a nonenzymatic 
role also facilitates the uptake of lipoprotein particles into tissues by anchoring them to the 
vessel wall and by serving as a ligand for the lipoprotein receptors [2–7].
Human LPL, a 448 amino acid protein, is encoded by the gene found on chromosome 8p22. 
Although a lack of an X-ray crystal structure has hindered full exploitation of the enzyme as 
a drug target, the strong homology with the pancreatic lipase has enabled the development of 
high-fidelity molecular models of the protein structure. Characteristic features of the lipase 
gene family such as a heparin-binding domain and an active site α/β hydrolase fold are 
found in the LPL protein structure. The protein is organized into two structurally distinct 
domains along with a 27 amino acid signal peptide. The bigger N-terminal domain contains 
a binding site for heparin and the site for binding of apolipoprotein C-II (APOC2) [8–10]. 
Also housed in the N terminus is the catalytic site of the enzyme comprising the triad: serine 
132, asparagine 156 and histidine 241 [11–13]. The smaller C-terminal domain has been 
shown to be important for binding lipoproteins. The active site of the LPL is covered by a 
‘lid; as seen in other homologs such as HL and PL [14]. The lid is postulated to have an 
impact on the substrate specificity of the lipase gene family and is essential for interaction 
with the lipid substrates [1,15,16]. Native LPL monomers dimerize in a head-to-tail fashion 
to form a noncovalent active dimer [17,18]. In this orientation, the C-terminal of one 
monomer is in close juxtaposition to the catalytic site of the other monomer in the dimer. In 
the most well accepted model of LPL activity, the lipid substrates are presented to the active 
site via interaction with the C-terminal of the protein. This dimerization process and the 
head-to-tail orientation are key to the activity of the enzyme because the monomers have 
been shown to be inactive [19,20].
The process of LPL maturation and transport is tightly controlled. The enzyme is 
synthesized in the parenchymal cells of the heart, muscle and adipose tissues and transported 
across to the luminal surface of the vascular endothelial cells. It was believed hitherto that, at 
the luminal site, the protein was anchored to the cells by heparan sulfate proteoglycans 
(HSPGs). This ionic interaction was considered the basis of the long-established procedure 
of using intravenous heparin injections to release the free LPL into plasma for collection and 
assay of its activity. However, the role of HSPGs in anchoring LPL on the luminal surface 
has been called into question with the recent discovery of a novel protein, now shown to be 
implicated in this process (discussed below). The intricate process of expression of active 
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lipase is only now being elucidated. Emerging evidence points to significant post-
translational processing of the inactive monomeric lipase in the endoplasmic reticulum (ER). 
A transmembrane lipase-specific chaperone named lipase maturation factor 1 (LMF1) was 
identified as having a crucial role in facilitating the assembly of inactive monomers of the 
enzyme into active homodimers as well as maintaining the stability of LPL dimer in the ER 
[21]. An intracellular loop of LMF1 is localized to the ER lumen wherein it interacts with 
LPL. Absence of LMF1 leads to accumulation of LPL as high molecular weight aggregates 
that are retained in the ER. LMF1 was also identified to be crucial for the maturation of 
other vascular lipases: HL and EL [22,23]. Physical interaction with each of the vascular 
lipases has been demonstrated. Indeed, mutation in the LMF1 gene underlies the syndrome 
of combined lipase deficiency (cld) and is characterized by massive hypertriglyceridemia 
and chylomicronemia with a 93% decrease in LPL activity [21]. Another mechanism 
controlling LPL activity recently emerged when an additional ER-associated factor was 
shown to mediate LPL secretion. This factor, suppressor of lin-12-like (Sel1L), is an ER-
localized adaptor protein that forms a complex with LPL and LMF1 and is required for the 
release of active LPL from the ER [24]. Sel1L knockout mice displayed severe postprandial 
hypertriglyceridemia and retention of LPL in the ER in the form of protein aggregates.
Until recently, it was believed that HSPGs played a crucial part in LPL binding in the 
interstitial space, its transport across the endothelial cells and its tethering on the surface of 
the capillary lumen. However, this traditionally accepted model of HSPG-mediated LPL 
binding, transport and tethering has been challenged recently by the discovery of another 
key protein facilitating the transport of LPL from the subendothelial space to the luminal 
surface of vascular endothelial cells: glycosylphosphatidylinositol-anchored high-density 
lipoprotein binding protein 1 (GPIHBP1). A small glyco-protein, GPIHBP1 has high affinity 
for LPL and has recently been shown to be responsible for the transendothelial transport of 
LPL from the parenchymal cells to the capillary lumen where it is postulated to provide a 
platform for lipolysis [25–27]. GPIHBP−/− mice showed delayed release of LPL upon 
heparin injection consistent with mislocalization of LPL. Further evidence has shown that 
GPIHBP1 is responsible for margination of triglyceride-rich lipo-proteins. By modulating 
LPL processing and transport, GBIHBP1 modulates triglyceride metabolism. Severe 
chylomicronemia has been reported in mice lacking GPIHBP1 [25]. In humans, the 
significance of GPIHBP1 in LPL biology has also been demonstrated with the existence of 
mutations in the GPIHBP1 gene that abolish its binding with LPL. In such mutants, 
chylomicronemia has been observed [28,29]. Additionally, LPL mutants that fail to bind 
GPIHBP1 show the similar phenotype of chylomicronemia [30]. Discovery and 
characterization of GPIHBP1 has led to a dramatic evolution of our understanding of LPL 
biology and will lead to further insights into the interplay between the enzyme, various 
accessory proteins, the apolipoproteins (APOs) and the triglyceride-rich lipoproteins.
As a crucial node in lipid metabolism and transport, LPL regulates plasma triglyceride 
levels. The FFAs that are the products of triglyceride hydrolysis are used by the underlying 
tissue in a tissue-specific manner. Whereas in heart and muscle, LPL-activity-derived FFAs 
are used as a source of energy, the ones in the adipose tissue are used for storage as fat 
depots. Adult liver can take up LPL from the circulation, wherein LPL activity can lead to 
increased fat deposition and compounded insulin resistance. The role of LPL in the nervous 
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system is slowly being unraveled. Immunostaining for LPL has been detected in the neurons, 
astrocytes, microglia and oligo-dendroglia throughout the central nervous system [31]. LPL 
has been shown to regulate energy balance and bodyweight in mice because a neuron-
specific deletion of LPL exhibits obese phenotype in mice fed standard chow [32]. Further, 
LPL function in Alzheimer’s disease pathology has been implicated in mouse studies 
showing cognition and memory deficits in LPL-deficient mice [33]. In addition to the 
adipose, muscle, heart and brain, LPL is also found in lactating mammary gland, 
macrophages, lung, kidney, spleen and testes [34,35]. Interestingly, macrophage-derived 
LPL has been ascribed a proatherogenic role with its catalytic activity and noncatalytic 
bridging action contributing to this effect. However, the relative contribution of macrophage 
LPL to overall physiological effects of LPL is unclear; a well-defined antiatherogenic 
activity has been noted in several mouse models of LPL overexpression probably via global 
lowering of plasma lipids [36–40]. Furthermore, several commercially available 
hypolipidemic and antidiabetic drugs (discussed below) are known to have LPL stimulatory 
activity that probably contributes to lowering of plasma lipids and improvement of 
cardiovascular outcomes [41–44]. Conversely, LPL deficiency in human studies has been 
shown to correlate with worsened atherosclerotic outcomes [45–47]. As such, in spite of the 
proatherogenic role of macrophage LPL, a large body of evidence suggests that LPL is a 
bona fide target in treating dyslipidemia and associated complications.
Several loss-of-function and gain-of-function studies have provided insight into the key role 
of LPL in metabolic homeostasis. The LPL knockout mouse models have shown a severe 
hypertriglyceridemic phenotype [48]. The homozygote knockouts are born with threefold 
higher triglyceride levels and sevenfold higher VLDL cholesterol levels. Upon suckling, the 
LPL knockout mice became pale, then cyanotic and finally died 18–24 hours after birth. 
Heterozygous LPL knockout mice survive to adulthood and have mild hypertriglyceridemia 
with 1.5–2-fold higher triglyceride levels than control mice [48]. Transgenic mice 
overexpressing LPL show markedly lower plasma TG and a resistance to diet-induced 
hypertriglyceridemia and hypercholesterolemia [40]. Tissue-specific LPL knockout and 
overexpression have facilitated a detailed understanding of LPL functions [32,49–51]. 
Overall, evidence points to the role of LPL in controlling partitioning of lipids toward either 
deposition or utilization pathways.
Regulation of LPL activity primarily occurs post-transcriptionally. A constellation of 
proteins plays a significant part in regulating LPL activity. These ‘LPL regulatory proteins’ 
are derived from the liver as well as other tissues (Fig. 1, Table 1). The roles of LMF1 and 
GPIHBP1 have already been stressed. Among other LPL regulatory proteins are the APOs 
and the angiopoietin-like proteins (ANGPTLs). On the basis of their function, LPL-
regulatory proteins can be grouped as either LPL-stimulatory or LPL-inhibitory proteins. 
APOC2 and APOA5 have been described to have LPL-stimulatory properties with APOC2 
recognized as a required cofactor for hydrolytic activity of LPL [52,53]. APOC2 is required 
for maximal rates of TG-rich lipoprotein lipolysis [52]. The C-terminal helix in APOC2 
guides lipoproteins to the active site of LPL [54,55]. APOC2 deficiency is associated with 
marked elevation of plasma TG, VLDL and chylomicron levels and decreased LPL activity, 
LDL, IDL and HDL levels [56]. Interestingly, higher concentrations of APOC2 lead to 
hypertriglyceridemia [57]. Although mechanisms of this dose effect are not clear, it is 
Geldenhuys et al. Page 4













speculated that, at high plasma concentrations, APOC2 produces impairment of lipolysis and 
a defect in remnant removal.
As opposed to APOC2 and APOA5, APOC1, APOC3 and APOE inhibit LPL-dependent TG 
clearance [58–61]. APOC3 is especially well characterized for its LPL inhibitory activity 
with known human heterozygous carriers of null mutation in the APOC3 gene exhibiting 
lower plasma TG levels [62]. Angiopoietin-like 3, 4 and 8 are well characterized LPL 
activity inhibitors. Modulation of LPL-regulatory proteins is emerging as an indirect means 
of targeting and regulating LPL for therapeutic use (described below). Among these, 
APOC3 and ANGPTL proteins have received the most attention.
APOC3 is found on APOB-containing lipoproteins like VLDL and LDL but unlike APOB is 
much smaller (only ~9 Kda) [63]. APOC3 has multiple roles in lipoprotein metabolism. As 
noted earlier, APOC3 inhibits LPL activity and thus TG lipolysis. It has been proposed that 
APOC3 inhibits LPL by displacing the enzyme from the lipid droplets [64]. Further, APOC3 
also inhibits receptor-mediated uptake of remnant lipoproteins and LDL. Large population-
based genome-wide association studies (GWAS) have highlighted the linkage between 
APOC3 and cardiovascular outcomes [65]. These observations have stimulated great interest 
in targeting APOC3 for lipid lowering, as will be discussed later in this review.
Emerging evidence suggests that ANGPTLs are key regulators of triglyceride and 
lipoprotein levels in humans [66]. Among this subfamily, prominent roles have been 
ascribed to ANGPTL3, ANGPTL4 and ANGPTL8 which are secretory proteins with a 
distinct expression pattern [67–71]. These proteins inhibit LPL found lining capillary 
endothelium in many tissues. Inhibition of LPL activity by ANGPTL3 and ANGPTL4 
results in elevated TGs in the bloodstream and a poor lipid profile. Injection of recombinant 
ANGPTL4 as well as peripheral overexpression of ANGPTL4 is associated with increased 
serum triglycerides, non-HDL cholesterol and nonesterified fatty acids (possibly because of 
stimulation of adipose tissue lipolysis) [68,72,73]. ANGPTL4 deficiency has been shown to 
improve total cholesterol, triglyceride and reduce foam cell formation thereby protecting 
against atherosclerosis [74]. However, similar to LPL, the macrophage-expressed ANGPTL4 
has distinct effects on atherosclerosis progression as opposed to non-macrophage 
ANGPTL4. The expression of ANGPTL4 in human atherosclerotic plaques and its 
localization to macrophages has been demonstrated [75]. Using apolipoprotein E (ApoE)*3-
Leiden (E3L) mice, authors showed that ANGPTL4 inhibits foam cell formation and 
promotes reduction in total lesion area. In another recent report, it was shown that 
ANGPTL4 expression is upregulated in foam cells [76]. Additionally, hematopoietic 
deficiency of ANGPTL4 was achieved by transplantation of bone marrow from Angptl4−/− 
mice into the Ldlr−/− mice. The mice with hematopoietic deficiency of ANGPTL4 showed 
larger atherosclerotic plaques and enhanced foam cell formation via increased CD36 
expression and reduced ATP-binding cassette subfamily A member 1 (ABCA1) localization 
at the cell surface. In the same study, the global deficiency of ANGPTL4 was shown to be 
protective against atherosclerosis contrasting the effects observed with the hematopoietic 
deficiency of ANGPTL4. Thus, although the precise role of ANGPTL4 is still being 
elucidated, it is evident that ANGPTL4 is a major player in the process of circulatory lipid 
homeostasis.
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Although the exact mechanism of ANGPTL4 inhibition of LPL remains unclear, several 
mechanisms have been proposed. First, it has been shown that co-incubation of ANGPTL4 
with LPL increases the abundance of inactive LPL monomers [77,78]. Additional evidence 
shows that ANGPTL4 overexpression results in the reduction of proportion of LPL dimers. 
Whether ANGPTL4 drives the dimer to monomer conversion irreversibly or whether 
ANGPTL4 is bound to LPL monomers, thereby driving this conversion, are points that are 
currently debatable in this model. Alternatively, it has also been proposed that ANGPTL4 
functions as a conventional noncompetitive inhibitor that binds to LPL to prevent the 
hydrolysis of the substrate and that a reversible complex between ANGPTL4 and LPL is 
formed [79]. Although three conserved polar residues within a 12 amino acid motif of 
ANGPTL4 are known to be required for interaction with LPL, the domains and residues of 
LPL involved in this interaction are unknown [77]. In yet another mechanism, evidence for 
ANGPTL4-mediated intracellular degradation of LPL has been proposed [80]. Co-
transfection of LPL and ANGPTL4 in CHO cells resulted in reduced intracellular LPL 
levels and in adipocytes derived from ANGPTL4−/− mice increased levels of mature LPL 
was found to accumulate. Moreover, it was observed that blocking ER-Golgi transport 
processes abolished the differences in the levels of LPL derived from wild-type and 
ANGPTL4 adipocytes suggesting that ANGPTL4 probably acts on LPL after its processing 
in the ER. Furthermore, physiological conditions of fasting and cold resulted in an inverse 
relationship between the ANGPTL4 and mature LPL levels in the wild-type mice but not in 
ANGPTL4−/− mice. These findings suggest that, in addition to the intravascular inhibition of 
LPL, ANGPTL4 also acts intracellularly to promote LPL degradation. This novel discovery 
will inform the development of future small molecule and antibody approaches to targeting 
this protein–protein interaction.
Pharmacological targeting of LPL
The recognition of LPL as a drug target has existed for several decades. LPL modulation has 
been shown to be a pleiotropic effect of several clinically used drugs in metabolic disorders. 
However, a clinically useful drug with LPL activation as its centerpiece mechanistic effect 
has not yet been achieved. Only recently, the emergence of ANGPTL proteins and a renewed 
interest in APO proteins has reinvigorated the quest for a LPL-targeted drug. Strategies to 
target LPL have yielded a wide range of pharmacological tools including multiple small 
molecules, monoclonal antibodies, peptides, antisense oligonucleotides and even gene 
therapy. The remainder of this review will discuss the pharmacological manipulation of LPL 
achieved by currently marketed drugs or approaches as well as highly encouraging clinical 
and preclinical candidates and approaches in development. The drugs and strategies have 
been grouped as either the ones directly acting on LPL or the ones acting indirectly via LPL 
regulatory proteins.
Direct LPL modulation
Clinically used drugs—As mentioned above, LPL activation has been found to be a 
pleiotropic effect of many clinically employed drugs, some of which have been used for 
several decades for metabolic disorders. Fibrates, such as gemfibrozil and fenofibrate, 
increase LPL activity accounting for their hypotriglyceridemic property. It was discovered 
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that these drugs modulate the transcriptional expression of several APOs and enzymes via 
the peroxisome proliferator activated receptor (PPAR)-α in the liver, leading to stimulation 
of LPL activity [81]. Particularly, fibrates inhibit the expression of APOC-III thereby 
enhancing the LPL activity [82]. Other notable effects of fibrates include their property to 
enhance beta-oxidation of fatty acids and inhibit VLDL synthesis and release from the liver 
[44]. These latter effects are probably of greater significance in triglyceride-lowering effects 
of these drugs. Statins, a significant lipid-lowering drug class, have also been shown to have 
an effect on LPL physiology. Atorvastatin enhances serum LPL levels in type 2 diabetics 
[83]. Similar clinical observations have been made for simvastatin [84]. This increased 
serum LPL seen in response to atorvastatin is suggested to occur via increased LPL 
production in the skeletal muscle in an adenosine-monophosphate-activated protein kinase 
(AMPK)-dependent mechanism [85]. Interestingly, the effects of statins on LPL occur in a 
tissue-specific manner with a decrease in LPL mass after statin administration also reported 
in macrophages [86]. Statins are known to have strong cholesterol-lowering properties by 
virtue of inhibition of HMG CoA reductase (HMG-CoA) and downstream upregulation of 
LDL receptor (LDL-R) on the surface of hepato-cytes. The triglyceride-lowering property of 
statins is often inadequate in cases of severe hypertriglyceridemia and requires 
supplementation with fibrates, niacin or omega 3 fatty acids [87]. The contribution, if any, of 
LPL regulation in statin activity is unclear. Among the many activities ascribed to ω-3 fatty 
acids is their regulation of LPL. Evidence suggests that ω-3 fatty acids regulate LPL directly 
via increasing the production of the enzyme as well as indirectly by inhibiting the expression 
of APOC3 from the liver [88–91].
LPL modulation has also been observed in glucose-lowering drugs. These include 
thiazolidinediones (TZDs) and metformin. A PPRE identified in the promoter region of the 
human LPL gene has been shown to mediate the TZD-induced expression of LPL in the 
adipose tissue [81]. PPAR-γ is also shown to increase the expression of carbohydrate 
sulfotransferase 11 (CHST11/C4ST1), a protein that is known to sulfate the membrane-
bound proteo-glycans that anchor the LPL protein to the cell surface [92]. Rosiglitazone was 
shown to induce the expression of GPIHBP1 in adipose tissue, heart and skeletal muscle. 
Further, knockdown of PPAR-γ was found to result in reduced GPIHBP1 expression [93]. 
Metformin regulation of LPL has been established in human clinical use and animal models 
with early evidence emerging over 30 years ago. Rats fed a fructose-rich diet and 
administered met-formin at 50 mg/kg/day showed higher plasma LPL activity and lower 
plasma TG than untreated fructose-fed rats [94]. Metformin induces the pre-heparin LPL 
mass in type 2 diabetic patients [95]. Cell culture studies have shown metformin activates 
LPL production in skeletal muscle downstream of AMPK [96]. Another indirect target of 
metformin in LPL physiology includes LMF1, the expression of which was increased by 
metformin in the heart and to a lesser extent in the muscle and adipose tissues of rats [97]. 
Whether LPL activation is the mechanism of lipid-lowering effects of these antidiabetic 
drugs has not been validated but evidence suggests that this activity probably contributes to 
the hypotriglyceridemic effects of the TZDs and metformin. Thus, whereas LPL modulation 
as a pharmacological property is seen in several pharmaceutical drugs, it is often a 
pleiotropic effect and not the principal mechanism of action of these drugs. Efforts to 
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intentionally target LPL activity have gained mainstream attention and from this point 
forward this review will summarize some of these promising new approaches (Table 2).
Experimental direct LPL activators—Development of direct LPL activators has been 
largely sporadic. An initial phase dominated by a single compound in the late 1990s was 
followed by prolonged inactivity in this area. Only recently has this been revived by two new 
molecules identified as a result of focused LPL-targeting efforts.
In 1993, researchers reported the identification of a novel compound named NO-1886 
(generic name: ibrolipim) as an activator of LPL [98]. In the initial study, NO-1886 was 
found to be an inducer of LPL gene expression in the adipose tissue leading to increased 
post-heparin plasma LPL activity, lower plasma triglycerides and higher plasma HDL. 
Further, the compound showed the property of inhibiting atherosclerotic lesion formation in 
vitamin-D2-treated cholesterol-fed rats upon prolonged administration. Similar results were 
observed in a rabbit model of atherosclerosis [99]. Single doses of NO-1886 were found to 
significantly stimulate LPL activity, lower plasma triglycerides and elevate the levels of 
HDL-C [100]. In streptozotocin (STZ)-treated diabetic rats, NO-1886 increased LPL activity 
59% over control [101]. The compound was tested in several other animal models of 
dyslipidemias and showed promising activity [102–107]. NO-1886 entered clinical 
development in Japan in the late 1990s. However, owing to unknown side effects, the clinical 
development of NO-1886 was halted. The compound did cause a species-specific effect on 
adrenal cortex steroidogenesis leading to hypertrophy of adrenal glands in rats and dogs 
although this effect was not observed in monkeys [108]. Nevertheless, to date, NO-1886 
remains the most extensively studied direct LPL activator.
Recently, two new molecules targeting LPL directly have emerged. Both these molecules 
differ from NO-1886 in respect to their mechanism of LPL activation. Whereas NO-1886 
primarily induces LPL mRNA resulting in an increase in LPL activity in plasma, the newer 
compounds primarily enhance the LPL hydrolytic activity having been identified in an in 
vitro enzyme activity screening assay. One of these newer compounds was identified in our 
laboratory in pilot screening of a small chemical library [109]. The initial hit compound 
identified in the screening assay (C10) was further optimized to yield a highly potent analog 
we named C10d. We compared the LPL activation property of C10d against NO-1886 and 
found that C10d exhibited twice the stimulation of LPL than NO-1886 did at equivalent 
doses. Interestingly, when we tested the efficacy of LPL activators in reversing the 
ANGPTL4 inhibition of LPL, C10 and C10d rescued the ANGPTL4 effects in a dose-
dependent manner. NO-1886, by contrast, does not reverse the ANGPTL4 inhibition of LPL 
in this in vitro assay. However, it is probabe that NO-1886 can rescue the ANGPTL4 
inhibition of LPL in vivo owing to its stimulatory effects on LPL gene expression. C10 and 
C10d do not have effects on LPL gene expression and only affect the enzymatic activity of 
LPL. Nevertheless, C10 and C10d represent a new class of LPL activators that can be 
optimized and developed further. Unpublished data from our laboratory suggest robust in 
vivo stimulation of LPL activity. The precise molecular mechanisms of LPL activation by 
these compounds are currently being studied in our lab.
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Another notable molecule that has recently been reported is an N-phenylthalimide derivative 
[110]. Identified in a small molecule screen set up to select compounds that protect LPL 
against inhibition by ANGPTL4, the researchers identified a molecule named 50F10 that 
exhibited potent activity in primary and secondary screens using different LPL substrates. 
Mechanistic studies showed that this molecule stabilizes the active homodimer structure of 
LPL and prevents its conversion to inactive monomers in the presence of ANGPTL4. In vivo 
evidence of activity in an APO A-V deficient mouse model challenged with olive oil gavage 
was also presented. Extensive SAR studies demonstrated that the phthalimide moiety and the 
lipophilic substituents as well as substitution pattern on the central phenyl ring are 
functionally essential to the activity of the compound [111]. SAR studies led to 
improvement of in vitro LPL activity and one such analog designated ‘80’ was tested in vivo 
where efficient plasma TG-lowering activity was shown.
Hypolipidemic activity was also demonstrated for indole-2-car-boxamide and benzofuran-2-
carboaxamide derivatives [112,113]. Although direct LPL activity of these compounds was 
not shown, their hypolipidemic activity was demonstrated in a rat model using anionic 
detergent Triton® WR-1339 which is known to prevent catabolism of TG-rich lipoproteins 
by LPL. Follow-up studies to elucidate the mechanism of these compounds were not 
reported.
LPL gene therapy—LPL gene deficiency (type 1 hyperlipidemia) is a rare (1–
2:1,000,000) autosomal-recessive disease [114,115]. Hyper-triglyceridemia, often resulting 
from chylomicronemia in these patients, can lead to severe pancreatitis that is recurring and 
life threatening. Traditionally, the treatment has been a drastic reduction in dietary fat intake. 
However, such dietary compliance is difficult to sustain and often ineffective. A gene 
therapy designed to introduce extra copies of the functional potent enzyme in the muscles of 
the lower limbs of patients was introduced in Europe in 2014 [116,117]. The genetic 
construct used to introduce functional LPL is an adenoassociated viral vector (AAV)-LPL 
S447X and the therapy is named alipogene tiparvovec (Glybera®). S447X, a naturally 
occurring gain-of-function mutation of LPL, has been extensively studied and is associated 
with a lower rate of cardiovascular disease (CVD) [118]. Initial preclinical evaluation of 
AAV LPLS447X in LPL−/− mice and cats demonstrated effectiveness in reducing lipemia and 
plasma triglycerides [119,120]. The clinical trials of alipogene tiparvovec in 27 patients with 
LPL deficiency showed a transient reduction in plasma TG levels [121]. Although the 
plasma TG levels rebounded to pre-treatment levels in 26 weeks after alipogene 
administration, the therapy was found to have a long term impact on chylomicron 
metabolism with a reduction in chylomicron TG content [122]. Patients have also shown 
expression of functional copies of the LPLS447X gene in long-term follow-up studies. It is 
postulated that chylomicrons are primarily responsible for pancreatitis. The incidence of 
pancreatitis declined with LPL gene therapy. Notably, the reduction in the incidence of 
pancreatitis was sustained up to 6 years after administration [123]. The therapy has been 
generally well tolerated with mild-to-moderate injection site reactions. The immune 
response against the AAV coat proteins has been observed which persists despite 
pharmacological suppression using immunosuppressants such as cyclosporine and 
mycophenolate mofetil. The immunosuppressants have been found not to affect the 
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production of the transgene in the body or impact the duration of TG lowering achieved 
[124]. This first of its kind gene therapy for LPL is a highly significant development for this 
rare genetic disease and its approval has paved the way for the development and regulatory 
approval of additional gene therapy products in a wide array of human diseases around the 
world.
Indirect LPL modulation
Apart from the excitement around novel small molecule activators of LPL and the 
groundbreaking gene therapy advances in LPL deficiency, there have been concerted efforts 
in industrial and academic laboratories to modulate LPL indirectly via regulation of 
expression or activity of LPL regulatory proteins. As discussed earlier and as shown in Table 
1, LPL functional activity is subject to regulation by a host of LPL regulatory proteins such 
as APOs and ANGPTLs. The discussion below will summarize the approaches around LPL 
regulatory proteins that have yielded clinical candidates in pharmaceutical and biotech 
pipelines, as well as other promising preclinical therapies.
Inhibition of APOC3—The changing paradigm on the role of TGs in CVD, from a risk 
factor to a causal relationship, has triggered a quest for druggable targets involved in 
regulation of plasma TGs. Owing to its dual inhibitory activities – on LPL and on that of 
liver uptake of remnant lipoproteins – APOC3 has emerged as a bona fide target in 
regulating the plasma levels of TG-rich lipoproteins. In a GWAS published in 2008, Pollin et 
al. uncovered the cardioprotective effect of APOC3 in the Lancaster Amish population 
among carriers of the null mutation in the APOC3 gene [62]. These carriers demonstrated 
low fasting and post-prandial plasma TG levels as well as high HDL and low LDL 
cholesterol levels. Moreover, they also exhibited lower levels of subclinical atherosclerosis 
as measured by coronary artery calcification. Recently, a large prospective study confirmed 
the causal association between high plasma TGs and CVD risk [125]. Moreover, 
investigators found that a loss of function mutation of APOC3 which is associated with low 
non-fasting plasma TG levels (44% lower than non-carriers) is also correlated with a low 
risk of ischemic vascular disease (41% risk reduction) and ischemic heart disease (36% risk 
reduction). Further, in an exome sequencing study to identify genes related with plasma TG 
levels, aggregate gene mutations in APOC3 (four mutations) were found to correlate with 
lower plasma TG levels. The carriers of any of the four APOC3 mutations were found to be 
at 40% lower risk for coronary heart disease [126]. The findings of APOC3 loss-of-function 
mutation were replicated in a newer report, wherein a multiethnic US adult population was 
studied [127]. Although the interest and the efforts to develop therapeutics around APOC3 
predate some of these large human population studies, the findings from these studies have 
provided additional validation of APOC3 as an attractive drug target in lipid-related risks for 
CVD.
Although efforts to target APOC3 using RNAi are underway, the methodology that has made 
the most headway is the antisense oligonucleotide platform developed by Ionis 
Pharmaceuticals. This antisense drug, named volanesorsen (formerly known as ISIS-
APOCIIIRx or ISIS 304801), is currently undergoing Phase III clinical trials in patients with 
hypertriglyceridemia and in patients with familial chylomicronemia syndrome (FCS). The 
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antisense technology used here is a chimeric oligonucleotide (a 20-mer) that binds the 
human APOC3 mRNA within the 3′-untranslated region and results in RNase H-mediated 
degradation of the APOC3 mRNA. The oligo is characterized by five 2′-O-(2-methoxyethyl)
(-MOE)-modified ribonucleotides at the 5′ and 3′ ends that confer increased affinity for the 
target mRNA, increased resistance to exo-and endo-nucleases and an improved safety profile 
[128–130]. The first studies on volanesorsen emerged in 2013, when the identification of 
this antisense oligo was reported from a screen of ~350 MOE chimeric candidates [131]. 
Authors demonstrated robust reduction in the plasma APOC3 levels along with reductions in 
plasma TGs in multiple animal models treated with volanesorsen. Reduction in plasma TGs 
was not a result of decreased hepatic VLDL-TG secretion or intestinal TG secretion but 
rather an increase in plasma TG clearance. No hepatic steatosis or other toxicity was 
observed for inhibition of APOC3. Favorable effects on plasma lipid profile were observed 
in rhesus monkeys. In the same publication, a Phase I human study was reported where the 
animal findings of APOC3 reduction, plasma TG reduction and safety profile were found to 
be validated. Promising data obtained in this study laid the groundwork for further human 
clinical development.
Interestingly, the drug development of APOC3 antisense oligonucleotide has also greatly 
informed the biology related to the triglyceride-elevating properties of APOC3. Novel 
findings regarding the role of APOC3 in triglyceride metabolism were brought to light in a 
Phase II clinical trial of volanesorsen in three patients with FCS [132]. These patients have 
genetic loss of function of mutation of LPL or one of the proteins necessary for LPL 
function and, as a result, have elevated levels of chylomicrons in the circulation which 
predisposes them to increased risk of severe pancreatitis and life threatening lipemia. 
Unexpectedly, volanesorsen showed remarkable activity of lowering plasma triglycerides in 
these patients without any appreciable increase in the residual LPL activity. The efficacy of 
volanesorsen in these patients led the authors to postulate the existence of a LPL-
independent pathway of triglyceride clearance and the inhibition of this pathway by APOC3. 
Although such APOC3 activity had earlier been proposed in a transgenic APOC3 mouse 
model, the findings obtained from the volanesorsen use in FCS have provided human proof-
of-concept validation of this hypothesis [133].
A bigger Phase II trial on hypertriglyceridemic patients was performed in a 13-week study 
with either volanesorsen monotherapy (41 patients receiving the drug and 16 receiving 
placebo) or with volanesorsen in combination with a stable fibrate therapy (20 receiving the 
combination and eight receiving the placebo) [134]. A dose-dependent decrease in the 
plasma APOC3 levels was observed in volanesorsen-treated patients with an accompanying 
decrease in plasma TG levels ranging from 31.3% to 70.9% over the placebo group. Using a 
novel high-throughput chemiluminescent ELISA, authors reported a decrease in APOC3 
associated with specific lipoproteins [135]. The therapy was generally well tolerated with no 
effects on renal or hepatic functions. Cutaneous erythema and pain at the injection site were 
the observed side effects in 13% of injections in monotherapy cohorts and 15% of injections 
in the combination cohort. One patient developed a serum-sickness-like reaction even 
though no antibodies against the antisense drug were detected. Another patient showed 
adverse events related to arterial graft stenosis after the final high dose (300 mg) of 
volanesorsen. In a recent report, the efficacy of volanesorsen in improving insulin sensitivity 
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was demonstrated in type 2 diabetes patients [136]. In a randomized double-blind trial, 15 
patients with HbA1c >7.5% and hypertriglyceridemia (TG levels: 200–500 mg/dl) were 
administered subcutaneous volanesorsen weekly for 15 weeks. Significant suppression of 
plasma APOC3 and TG levels was seen along with a 57% improvement in whole-body 
insulin sensitivity as measured using a two-step hyperinsulinemiceuglycemic-clamp 
procedure. Sustained suppression (up to 3 months post-dosing) of Hba1c was observed. 
Overall, the clinical development of volanesorsen has brought attention to the roles of LPL 
and APOC3 in triglyceride metabolism and sparked great interest in more-rigorous studies 
around these two proteins.
Volanesorsen is not the only product under development to target APOC3. Examination of 
pharmaceutical and biotech product pipelines and reports from scientific congresses have 
revealed other products and strategies in development against APOC3. These include RNAi-
based approaches reported by Arbutus Pharmaceuticals, using lipid nanoparticles as delivery 
vehicles. RNAi against APOC3 and a combination RNAi product targeting APOC3 and 
ANGPTL3 have been reported (Keystone Symposium 2015; http://investor.arbutusbio.com/
releasedetail.cfm?releaseid=903410). Investigators have observed robust and durable 
inhibition of plasma TG and APOC3 levels in vitro and in an in vivo APOC3 transgenic 
mouse model treated with APOC3 RNAi. The combination RNAi (APOC3 + ANGPTL3) 
was observed to demonstrate super-additive effects over individual RNAi on plasma TG 
lowering in a high-fat-diet model of hypertriglyceridemia.
Hepatocyte-targeted delivery of APOC3 siRNA via N-acetylga-lactosamine (GalNAc) 
ligand conjugation underwent preclinical development by Alnylam Pharmaceuticals [137]. 
GalNAc serves as the ligand for the hepatocyte-specific asialoglycoprotein receptor 
(ASGPR) to facilitate liver-targeted delivery of the oligonucleotide. Early studies have 
shown a strong persistent (up to 30 days) knockdown of APOC3 levels in the liver by single 
doses (3 mg/kg) of these siRNAs (ALN-APOC3) delivered by the subcutaneous route in a 
mouse model transduced with AAV construct expressing human APOC3 gene (http://
investors.alnylam.com/releasedetail.cfm?ReleaseID=883469). Multi-dose studies have 
shown persistent knockdown of up to 35 days. In a db/db mouse model, a >90% lowering of 
plasma APOC3 and a >50% reduction of plasma TGs were observed. Similar efforts to 
inhibit ANGPTL3 via GalNAc tagging of siRNA are also being undertaken (mentioned 
below).
Inhibition of ANGPTL family members—The interest in developing targeted therapies 
against ANGPTL-mediated modulation of LPL is just as strong as for the APOC3. The 
strategy against ANGPTL3 that has stood out the most so far is the monoclonal antibody 
being developed by Regeneron Pharmaceuticals. Using their proprietary fully human 
antibody development platform named VelocImmune®, the investigators have developed a 
fully human monoclonal antibody that targets ANGPTL3 [138]. The product is named 
evinacumab (also called REGN1500) and is in Phase II clinical trials. Early studies have 
demonstrated significant activity of the antibody in extensive preclinical testing [139]. The 
antibody demonstrates specificity for ANGPTL3 and does not show any cross-reactivity 
with ANGPTL4, 5 and 8. The antibody was found to enhance post-heparin LPL activity in 
normolipidemic mice and lower plasma TGs by >50%. Further, chronic testing (8 weeks) in 
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high-fat- and high-cholesterol-fed dyslipidemic mice showed reduced plasma TG, plasma 
LDL-C and HDL-C levels. Administration of a single dose of the antibody in dyslipidemic 
cynomolgus monkeys exhibited similar activity on plasma lipids. REGN1500 has also 
proven to be a useful tool in the study of biological functions of ANGPTL3. Using this 
antibody, a study has recently demonstrated that inactivation of ANGPTL3 leads to 
increased clearance of APOB-containing lipoproteins and decreased production of LDL in 
ANGPTL3-deficient animals [140]. Indeed, emerging clinical data for REGN1500 validates 
these preclinical findings. Interim data from an ongoing Phase II clinical study in 
homozygous familial hypercholesterolemia (HoFH) patients shows that adding REGN1500 
to a lipid-lowering therapy (statin + ezetimibe; one patient also received additional 
lomitapide) causes a mean 55% (25–90%) reduction in LDL-C at 4 weeks over baseline with 
no adverse effects (http://files.shareholder.com/downloads/REGN/2807302673x0x894306/
C8D4BE1B-4EB3-4E8D-9DE8-8FCBACEB8975/
REGN_News_2016_5_31_General_Releases.pdf).
Notably, the efforts to target a related member of the ANGPTL family, ANGPTL4, preceded 
the antibody efforts around ANGPTL3. However, the inhibition of ANGPTL4 produced 
safety concerns when genetic ablation of ANGPTL4 in mice led to intestinal abnormalities 
with mucosal thickening, infiltration of foamy macrophages and lipogranulomatous 
inflammation in the mesenteric lymph nodes [141]. Reduced viability of ANGPTL4−/− mice 
was also observed. The surviving ANGPTL4−/− mice when weaned onto a high fat diet 
showed decreased survival compared with wild-type mice on a high fat diet or the knockout 
mice on a chow diet, and developed chylous ascites. Similar pathological findings in the 
mesenteric lymphatics and lymph nodes were seen in high-fat-diet-fed APOE−/− or LDLr−/− 
mice treated with anti-ANGPTL4 antibody. In a follow-up study, it was indeed demonstrated 
that mice lacking ANGPTL4 developed fibrinopurulent peritonitis, ascites, intestinal fibrosis 
and cachexia upon saturated fat intake. Induction of macrophage ANGPTL4 by fatty acids 
was shown to inhibit the fatty acid uptake into mesenteric lymph node macrophages thereby 
preventing the macrophage activation and uncontrolled fat-induced inflammation [142].
Another candidate to enter clinical development against ANGPTL3 is being pursued by 
Ionis Pharmaceuticals, using the similar antisense approach that has been used in the 
development of volanesorsen. The drug is named IONIS ANGPTL3-LRx (formerly ISIS 
703802 or ISIS-ANGPTL3 Rx) and is a ligand-conjugated antisense aimed to enhance the 
liver-specific delivery of the oligonucleotide. Studies from the unconjugated antisense 
product have been reported. Although modest effects of the antisense oligonucleotide were 
seen in normocholesterolemic mice, potent reductions in plasma TG (up to 88%) and 
cholesterol (up to 66%) along with reduced atherosclerosis were seen in LDLr−/− mice 
[143]. In a Phase I study, ISIS-ANGPTL3 Rx showed an acceptable safety profile and dose-
dependent reductions in plasma ANGPTL3 (82%), TG (49%) and total cholesterol (28%) 
[143]. Patients with higher baseline TGs showed a higher reduction in plasma TGs. The 
development of this drug is ongoing and is currently recruiting for a Phase II study testing 
safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers with 
elevated TGs and in patients with FCS (NCT02709850).
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GalNAc conjugation of ANGPTL3 siRNA has also been explored in preclinical studies 
[137,144]. Encouraging data in female ob/ob mice have shown a dose-dependent and robust 
(>99%) knockdown of serum ANGPTL3. A single 3 mg/kg dose in these mice produced an 
80% reduction in serum LDL-C and TGs. Another preclinical candidate reported is the 
combination RNAi product (Arbutus Pharmaceuticals) described earlier. Overall, we 
anticipate that ANGPTL3 will continue to be of pharmacological interest in dyslipidemias 
and hyperlipidemias for the foreseeable future.
Activation of APOC2—Several other APOs play a crucial part in post-translational 
modification of LPL function and activity. Among these, a stimulatory role has been 
ascribed to APOC2. Comprising three amphipathic helices, the C terminus of the protein is 
known to activate LPL. Interestingly, a marked elevation in the levels of APOC2 results in 
inhibition of LPL activity rather than stimulation of activity [57]. Nevertheless, APOC2 
levels have been correlated with plasma LPL activity and TG levels. There is interest in 
developing APOC2 mimetic peptides that can enhance the activity of LPL and result in 
enhanced hydrolysis of lipoprotein TGs. In a 2014 publication, researchers reported the 
development of an APOC2 mimetic peptide named C-II-a, containing a 21 amino acid motif 
of the third amphipathic helix of APOC2 connected to a synthetic amphipathic peptide 
named 18A [145]. The resultant synthetic bi-helical peptide is bifunctional with the 
properties of stimulating triglyceride hydrolysis (via the third helix of APOC2) and of 
promotion of cholesterol efflux by the ABCA1 transporter (via the 18A peptide). The 
APOC2 motif in C-II-a was found to recapitulate the activity of the full length APOC2 
protein in LPL activity assays. Further, in vivo evaluation of the peptide in the APOE−/− 
mouse model showed significant activity of lowering plasma triglycerides and plasma 
cholesterol. Further evaluation of the same peptide in APOC2 mutant mice showed the 
ability to correct the hypertriglyceridemia in these mice [146]. Although preliminary in 
nature, these studies provide crucial proof-of-concept validation for APOC2 mimetic 
peptides as pharmacological tools.
Concluding remarks
Over the past 5–10 years, LPL has attracted significant pharmacological attention in the 
treatment of metabolic disease and the downstream cardiovascular sequelae. Increased 
efforts of understanding of LPL physiology in recent years have led to identification of 
ANGPTL proteins GPIHB1 and LMF1 as key players in LPL biology, revitalizing the 
interest in LPL as a drug target. The pursuit of the approaches outlined in this manuscript 
and development of other novel modalities of targeting LPL are expected to continue.
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The liver–LPL axis. Lipoprotein lipase (LPL) hydrolyzes the circulatory triacylglycerol 
(TG)-rich lipoproteins [very-low-density lipoproteins (VLDL) and chylomicrons derived 
from the liver and the intestine, respectively] with the resulting decrease in plasma TG 
levels. The maturation, transport and anatomical localization of LPL form a multistep 
process with the participation of lipase maturation factor 1 (LMF1) and 
glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 
(GPIHBP1). The liver is a primary source of several LPL regulatory proteins with either pro-
LPL functions [apolipoprotein (APO)C2 and APOA5] or anti-LPL function [APOC1, 
APOC3, angiopoietin-like protein (ANGPTL)3, ANGPTL4 and ANGPTL8].
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TABLE 1
LPL regulatory proteins
Name Expression Modulation of LPL and proposed mechanisms Refs
Pro-LPL proteins
APOC2 Liver, colon Stimulation of LPL activity; high concentrations reported to 
inhibit LPL activity
[52,57]
APOA5 Liver, intestine, placenta Stimulation of LPL activity; multiple mechanisms have been 
proposed including direct interaction with LPL and heparan 
sulfate proteoglycans
[53]
GPIHBP1 Adipose, heart, breast, skin, endocrine 
glands
Transport of LPL from subendothelial space to the capillary 
lumen
[25–27]
LMF1 Endometrium, testis, lung, kidney, 
stomach, skeletal muscle, adipose, brain
Promotes maturation of LPL via assembly of inactive 
monomers into active dimers; transport of active LPL dimer in 
the secretory pathway from the cells
[21]
Sel1L Ubiquitous, strongest in the pancreas Forms complex with LPL and LMF1 and is required for the 
release of active LPL from ER
[24]
Anti-LPL proteins
APOC1 Liver, colon Inhibition of LPL activity; displaces LPL from the lipid droplets [59]
APOC3 Liver, intestine Inhibition of LPL activity; displaces LPL from the lipid droplets [60]
APOE Hippocampus, cerebral cortex, 
cerebellum, adrenal gland, liver, skin, 
kidney, testis
Inhibition of LPL activity [58,61]
ANGPTL3 Liver Inhibition of LPL activity; does not alter LPL self-inactivation 
rate
[66,69,71]
ANGPTL4 Adipose, skeletal muscle, lung, cerebral 
cortex, kidney, cerebellum, thyroid gland, 
adrenal gland and others
Inhibition of LPL activity; accelerates irreversible inactivation 
of LPL; probably mechanisms include conversion of active 
dimers to inactive monomers and noncompetitive reversible 
binding to LPL
[66,71,74,77,78]
ANGPTL8 Liver, brain, adipose tissue, lung Inhibition of LPL activity; promotes cleavage and activation of 
ANGPTL3
[70]
Abbreviations: ANGPTL3, angiopoietin-like 3; ANGPTL4, angiopoietin-like 4; ANGPTL8, angiopoietin-like 8; APOA5, apolipoprotein AV; 
APOC1, apolipoprotein C1; APOC2, apolipoprotein C2; APOC3, apolipoprotein C3; APOE, apolipoprotein E; GPIHBP1, 
glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1; LMF1, lipase maturation factor 1; LPL, lipoprotein lipase; Sel1, 
suppressor of lin-12-like.
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